Literature DB >> 15710736

Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension.

Y Fukumoto, T Matoba, A Ito, H Tanaka, T Kishi, S Hayashidani, K Abe, A Takeshita, H Shimokawa.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15710736      PMCID： PMC1768747          DOI： 10.1136/hrt.2003.029470

Source DB:  PubMed          Journal:  Heart        ISSN： 1355-6037            Impact factor:   5.994


× No keyword cloud information.
  5 in total

Review 1.  Signal transduction by G-proteins, rho-kinase and protein phosphatase to smooth muscle and non-muscle myosin II.

Authors:  A P Somlyo; A V Somlyo
Journal:  J Physiol       Date:  2000-01-15       Impact factor: 5.182

2.  Possible involvement of Rho-kinase in the pathogenesis of hypertension in humans.

Authors:  A Masumoto; Y Hirooka; H Shimokawa; K Hironaga; S Setoguchi; A Takeshita
Journal:  Hypertension       Date:  2001-12-01       Impact factor: 10.190

Review 3.  Rho-kinase as a novel therapeutic target in treatment of cardiovascular diseases.

Authors:  Hiroaki Shimokawa
Journal:  J Cardiovasc Pharmacol       Date:  2002-03       Impact factor: 3.105

Review 4.  Primary pulmonary hypertension.

Authors:  James R Runo; James E Loyd
Journal:  Lancet       Date:  2003-05-03       Impact factor: 79.321

5.  Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats.

Authors:  Kohtaro Abe; Hiroaki Shimokawa; Keiko Morikawa; Toyokazu Uwatoku; Keiji Oi; Yasuharu Matsumoto; Tsuyoshi Hattori; Yutaka Nakashima; Kozo Kaibuchi; Katsuo Sueishi; Akira Takeshit
Journal:  Circ Res       Date:  2003-12-11       Impact factor: 17.367
  5 in total
  90 in total

Review 1.  The role of Rho protein signaling in hypertension.

Authors:  Gervaise Loirand; Pierre Pacaud
Journal:  Nat Rev Cardiol       Date:  2010-08-31       Impact factor: 32.419

2.  Effects of acute Rho kinase inhibition on chronic hypoxia-induced changes in proximal and distal pulmonary arterial structure and function.

Authors:  Rebecca R Vanderpool; Ah Ram Kim; Robert Molthen; Naomi C Chesler
Journal:  J Appl Physiol (1985)       Date:  2010-11-18

Review 3.  Medical therapies for pulmonary arterial hypertension.

Authors:  Tomas Pulido; Nayeli Zayas; Maitane Alonso de Mendieta; Karen Plascencia; Jennifer Escobar
Journal:  Heart Fail Rev       Date:  2016-05       Impact factor: 4.214

4.  Direct effects of Rho-kinase inhibitor on pial microvessels in rabbits.

Authors:  Masakazu Kotoda; Tadahiko Ishiyama; Noriyuki Shintani; Takashi Matsukawa
Journal:  J Anesth       Date:  2014-08-24       Impact factor: 2.078

5.  Acute vasodilator effects of inhaled fasudil, a specific Rho-kinase inhibitor, in patients with pulmonary arterial hypertension.

Authors:  Hiroshi Fujita; Yoshihiro Fukumoto; Kenya Saji; Koichiro Sugimura; Jun Demachi; Jun Nawata; Hiroaki Shimokawa
Journal:  Heart Vessels       Date:  2010-03-26       Impact factor: 2.037

Review 6.  Rho kinase (ROCK) inhibitors.

Authors:  James K Liao; Minoru Seto; Kensuke Noma
Journal:  J Cardiovasc Pharmacol       Date:  2007-07       Impact factor: 3.105

Review 7.  Therapeutic potential of RhoA/Rho kinase inhibitors in pulmonary hypertension.

Authors:  M Oka; K A Fagan; P L Jones; I F McMurtry
Journal:  Br J Pharmacol       Date:  2008-06-09       Impact factor: 8.739

Review 8.  Rho kinases in cardiovascular physiology and pathophysiology: the effect of fasudil.

Authors:  Jianjian Shi; Lei Wei
Journal:  J Cardiovasc Pharmacol       Date:  2013-10       Impact factor: 3.105

Review 9.  Rho-kinase inhibitors as therapeutics: from pan inhibition to isoform selectivity.

Authors:  C Hahmann; T Schroeter
Journal:  Cell Mol Life Sci       Date:  2009-11-12       Impact factor: 9.261

Review 10.  Applications for ROCK kinase inhibition.

Authors:  Michael F Olson
Journal:  Curr Opin Cell Biol       Date:  2008-02-20       Impact factor: 8.382
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.